DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance
by Zacks Equity Research
Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.
Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?
by Zacks Equity Research
Computer Programs (CPSI) is likely to gain from TruBridge platform in fourth-quarter 2018.
BD Gains From Solid Global Base, Headwinds Anticipated
by Zacks Equity Research
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.
3 Medical Instruments Stocks Likely to Beat Estimates in Q4
by Zacks Equity Research
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?
by Zacks Equity Research
McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.
What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
by Zacks Equity Research
ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.
NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y
by Zacks Equity Research
NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.
What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.
Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?
by Zacks Equity Research
Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.
Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally
by Zacks Equity Research
Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.
PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong
by Zacks Equity Research
PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.
Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid
by Zacks Equity Research
Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.